Упрощенная HTML-версия
342.
Mechanisms of antihyperglycemic effects of moxonidine in the obese
spontaneously hypertensive Koletsky rats / P. Ernsberger [et al.] // J. Pharmac
Exp Therap. – 1999. – Vol. 288. – P. 139 – 147.
343.
Mehta J. L. Inflammation in ischemic heart disease: response to tissue injury or
a pathogenetic villain? / J. L. Mehta, D. Y. Li // Cardiovasc. Res. – 1999. –
Vol. 43, № 2. – P. 291-299.
344.
Messerli F. Moxonidine: a new and versatile antihypertensive / F. Messerli // J.
Cardiovasc. Pharmacol. – 2005. – Vol. 35, № 7, (Suppl. 4). – P. 53-56.
345.
Metabolic syndrome in middle-aged Finnish population / M. G. Vanhala [et
al.] // J. Cardiovase. Risk. – 1997. – Vol. 4. – P. 291-295.
346.
Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular
events: the Northern Manhattan Study (NOMAS) / T. Suzuki [et al.] // Am.
Heart. J. – 2008. – Vol. 156, № 2. P. 405 – 410.
347.
Metabolic Syndrome, Inflammation and Atherosclerosis / R. Paoletti [et al.] //
Vasc. Health. Risk. Manag. – 2006. – Vol. 2, № 2. – P. 145 – 152.
348.
Mild cognitive impairment: clinical characterization and outcome / Petersen R.
S. [et al.] // Arch. Neurol. – 1999. – V. 56. – Р. 303-308.
349.
MOSES Study Group. Morbidity and mortality after Stroke-Eprosartan
compared with nitrendipine for Secondary Prevention / J. Schrader [et al.] //
Stroke. – 2005. – Vol. 36, № 6. – P. 1218-1226.
350.
Moxonidine improves insulin sensitivity in insulin – resistant hypertensives /
A. Haenni [et al.] // J. Hypertension. – 1999. – Vol. 17 (suppl. 3). – P. 29 – 39.
351.
Moxonidine improves insuslin resistance in obese, insulinresistant patients
with moxonidine / A. Haenni [et al.] // J. Hypertens. – 1999. – Vol. 17. – P. 24
– 35.
352.
Moxonidine in the treatment of overweight and obese patients with the
metabolic syndrome: a postmarketing surveillance study / A. M. Sharma [et
al.] // J. Human Hypertens. – 2004. – Vol. 18. – P. 669-675.